Vandria announces first subjects dosed in its first-in-human Phase 1 clinical trial of VNA-318 brain-penetrant mitophagy inducer
LAUSANNE, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class...